miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026

View original at globenewswire.com
BioNTech präsentiert auf der 44. J.P…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BioNTech currently expects no revenues from oncology product sales in 2026

    80% confidence

  • 2026 is a year when scientific progress becomes tangible results for BioNTech, with milestones including late-stage data releases, early clinical trial results for combination therapies, and launch of additional Phase 3 trials

    80% confidence

  • BioNTech closed 2025 with strong momentum through consistent execution in R&D, partnerships, acquisitions, and strong financial position while advancing next wave of innovations including combination studies

    80% confidence

  • BioNTech expects collaboration revenues from Bristol Myers Squibb partnership in 2026 to be essentially at 2025 levels

    80% confidence

  • BioNTech has positioned itself as a biopharmaceutical company with multiple programs in late-stage clinical development

    80% confidence

  • Positive clinical trial results could pave the way for multiple short- and medium-term product launches, bringing BioNTech closer to helping patients with various cancer types

    80% confidence

  • BioNTech expects at least 17 late-stage clinical data readouts through 2030 and beyond, including from registration-enabling studies, to inform decisions on multiple potential product launches and establish BioNTech as a multi-product oncology company by 2030

    80% confidence

  • BioNTech expects moderate decline in Comirnaty revenues in 2026 compared to 2025, reflecting current COVID-19 vaccine market dynamics influenced by changing vaccination recommendations especially in the United States and transition from multi-year contracts to private markets

    80% confidence

  • BioNTech plans to start six additional Phase 3 clinical trials in 2026, bringing total expected Phase 3 trials to 15 by year-end

    80% confidence

Data points we hold from this source

BioNTech SE · phase 2 3 trials count25 trials
BioNTech SE · combination therapy trials count10 trials
BioNTech SE · phase 3 trials count15 trials
BioNTech SE · cash17.2 billion_EUR
BioNTech SE · revenue2.6-2.8 billion_EUR

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026 — Source | Via News | es.VIA.NEWS